You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Dow
Merck
Boehringer Ingelheim
McKesson
Medtronic
Baxter

Last Updated: February 20, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021945


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

NDA 021945 describes MAKENA (AUTOINJECTOR), which is a drug marketed by Amag Pharma Usa and is included in one NDA. It is available from two suppliers. There are nine patents protecting this drug. Additional details are available on the MAKENA (AUTOINJECTOR) profile page.

The generic ingredient in MAKENA (AUTOINJECTOR) is hydroxyprogesterone caproate. There are twelve drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the hydroxyprogesterone caproate profile page.
Summary for 021945
Tradename:MAKENA (AUTOINJECTOR)
Applicant:Amag Pharma Usa
Ingredient:hydroxyprogesterone caproate
Patents:9
Formulation / Manufacturing:see details
Pharmacology for NDA: 021945
Suppliers and Packaging for NDA: 021945
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MAKENA hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945 NDA AMAG Pharmaceuticals, Inc. 64011-243 64011-243-01 1 VIAL, GLASS in 1 CARTON (64011-243-01) > 5 mL in 1 VIAL, GLASS
MAKENA PRESERVATIVE FREE hydroxyprogesterone caproate SOLUTION;INTRAMUSCULAR 021945 NDA AMAG Pharmaceuticals, Inc. 64011-243 64011-243-01 1 VIAL, GLASS in 1 CARTON (64011-243-01) > 5 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULARStrength1250MG/5ML (250MG/ML)
Approval Date:Feb 3, 2011TE:AP1RLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAMUSCULARStrength250MG/ML (250MG/ML)
Approval Date:Feb 19, 2016TE:APRLD:Yes

Profile for product number 004

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;SUBCUTANEOUSStrength275MG/1.1ML (250MG/ML)
Approval Date:Feb 14, 2018TE:RLD:Yes
Patent:  Start TrialPatent Expiration:May 2, 2036Product Flag?Substance Flag?Delist Request?
Patented Use:REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
AstraZeneca
Mallinckrodt
Medtronic
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.